Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer

Japanese Journal of Clinical Oncology

Volumn 33, Issue 3, 2003, Pages 127-131

  Kawai, Koji ^a   Miyazaki, Jun ^a   Tsukamoto, Sadamu ^a   Hinotsu, Shiro ^a   Hattori, Kazunori ^a   Shimazui, Toru ^a   Akaza, Hideyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cisplatin; Ifosfamide; Paclitaxel; Testicular cancer

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PEPLEOMYCIN; RANITIDINE; VINBLASTINE; VINCRISTINE; TAXOID; TIP REGIMEN;

ADULT; ADVANCED CANCER; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG INFUSION; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FOLLOW UP; GERM CELL TUMOR; HEMATOLOGIC DISEASE; HUMAN; JAPAN; LEUKOPENIA; LIVER DYSFUNCTION; LONGITUDINAL STUDY; LUNG METASTASIS; MALE; MOTOR NEUROPATHY; MYALGIA; NEUROTOXICITY; SALVAGE THERAPY; SENSORY NEUROPATHY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VISCERAL METASTASIS; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MORTALITY; NEOPLASM; PHASE 2 CLINICAL TRIAL; TESTIS TUMOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; HUMANS; IFOSFAMIDE; LEUKOPENIA; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PACLITAXEL; SALVAGE THERAPY; TAXOIDS; TESTICULAR NEOPLASMS;

EID: 0037505857     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg029     Document Type: Article

References (20)

1. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, et al. Paclitaxel, ifosfamide and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18:2413-8.
2. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990;8:1777-81.
3. Farhat F, Culine S, Theodore C, Bekradda M, Lacombe MJT, Droz JP. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. Cancer 1996;77:1193-7.
4. McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. J Clin Oncol 1997;15: 2559-63.
5. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998;16:2500-4.
6. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997;15:2546-52.
7. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 1999; 17:3450-6.
8. Baniel J, Foster RS, Gonin R, Messemer SE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170-6.
9. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
10. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987;316:1435-40.
11. Motzer RJ, Bajorin DF, Schwartz LH, Hutter H, Bosl GJ, Scher HI, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994;12:2277-83.
12. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol 1994; 120:754-7.
13. Motzer RJ, Chou TC, Schwartz L, Bosl GJ, Bajorin DF, Hutter H. Paclitaxel in germ cell cancer. Semin Oncol 1995;22(3 Suppl 6):12-5.
14. de Wit R, Louwerens M, de Mulder PHM, Verweij J, Rodenhuis S, Schornagel J. Management of intermediate-prognosis germ-cell cancer: Results of a phase I/II study of taxol-BEP. Int J Cancer 1999;83:831-3.
15. Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, et al. Salvage treatment with paclitaxel, ifosfamide and cisplatin plus high-dose carboplatin, etoposide and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001;19:81-8.
16. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18:1173-80.
17. Hilkens PHE, Pronk LC, Verweij J, Vecht CJ, van Putten WLJ, van den Bent MJ. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997;75:417-22.
18. Berger T, Malayeri R, Doppelbauer A, Krajnik G, Huber H, Auff E, et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 1997;33:1393-9.
19. Porcu, P, Bhatia S, Sharma M, Einhorn LH. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 2000;18:1181-6.
20. Miyazaki J, Miyanaga N, Kawai K, Shimazui T, Takeshima H, Akaza H. High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer. Int J Urol 2000;7:258-62.